Parexel's Exciting Leadership Change
Parexel, a leading clinical research organization (CRO), recently made headlines with the appointment of Keri Mattox as their Chief Business Officer. This new position marks a pivotal moment for Parexel as they continue to expand their influence in the clinical development landscape.
A New Vision for Growth
With over 25 years of experience in the healthcare sector, Ms. Mattox is set to take the reins of Parexel's business operations and growth strategy. Her diverse background spans corporate strategy, investor relations, and environmental, social, and governance (ESG) initiatives. Ms. Mattox's proven expertise will be invaluable as she collaborates with Parexel's senior leadership team, reporting directly to CEO Peyton Howell.
Keri Mattox's Background
Before joining Parexel, Keri Mattox held significant roles in notable companies. She was the Chief Communications and Administration Officer at Zimmer Biomet, where she contributed to a global leader in medical technology. Furthermore, her previous positions include Global Lead of Integrated Corporate Communications at W2O Group and Vice President of Corporate & Investor Relations at AmerisourceBergen, a Fortune 20 company. Her career trajectory showcases her extensive experience and competence in driving communication strategies and corporate development.
A Commitment to Patients and Innovation
In her own words, Ms. Mattox expressed her enthusiasm for joining Parexel during this transformative time. She emphasizes Parexel’s commitment to operational excellence and a patient-first approach, stating that the company provides biopharmaceutical firms with integrated solutions to accelerate therapies to market. With her leadership, Parexel aims to enhance their global footprint, driving growth in key segments and reaching new frontiers in innovation.
About Parexel
Parexel stands at the forefront of the clinical research industry, dedicated to providing comprehensive Phase I to IV clinical development services. Their mission is to facilitate the faster availability of life-saving treatments to patients worldwide. With a dedicated team of over 21,000 professionals, they partner with biopharmaceutical leaders, emerging innovators, and research sites to conduct clinical trials geared toward patient needs. Their commitment is reflected in their recognition, having received prestigious awards like the Society for Clinical Research Sites Eagle Award for consecutive years and accolades as a top CRO to work with globally.
The Future of Clinical Research
Parexel’s innovative ecosystem enhances the efficiency of each phase of the clinical trial process, striving to ensure that clinical research becomes a viable care option for everyone, regardless of their location. Their focus on operational excellence and understanding patient experiences helps to bridge the gap in healthcare’s complex territory, ultimately paving the way for better treatments and care.
Frequently Asked Questions
What is the significance of Keri Mattox's appointment at Parexel?
Keri Mattox's appointment as Chief Business Officer signifies a strategic shift for Parexel, allowing the company to leverage her extensive experience in healthcare to drive growth and innovation.
What prior experience does Keri Mattox bring to her new role?
Keri Mattox brings over 25 years of experience in corporate strategy, investor relations, and communications, having held leadership roles at Zimmer Biomet and AmerisourceBergen, among others.
How does Parexel plan to expand its global footprint?
Parexel intends to expand its global presence by driving growth in key segments, enhancing patient-focused solutions, and innovating clinical processes.
What awards has Parexel received in recent years?
Parexel has been recognized with the Society for Clinical Research Sites Eagle Award and named the “Best Contract Research Organization” by an independent panel for Citeline.
How does Parexel support patient-focused clinical trials?
Parexel supports patient-focused clinical trials by increasing access and participation, utilizing a dedicated team to ensure that trials meet patient needs effectively.
